Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Penicillamine
Drug ID BADD_D01709
Description Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Indications and Usage For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.
Marketing Status approved
ATC Code M01CC01
DrugBank ID DB00859
KEGG ID D00496
MeSH ID D010396
PubChem ID 5852
TTD Drug ID D08HZC
NDC Product Code 59285-014; 76339-159; 0254-2000; 68682-020; 70010-907; 0591-4171; 68022-7041; 72640-012; 25010-705; 60505-4696; 62559-970; 71205-916; 0037-4401; 62207-013; 71052-491; 43598-634; 51991-974; 70748-153; 42973-230; 51552-1096; 49884-146; 68475-201; 59651-245; 70159-004; 76003-0870
UNII GNN1DV99GX
Synonyms Penicillamine | Mercaptovaline | D-Penicillamine | D Penicillamine | Dimethylcysteine | beta,beta-Dimethylcysteine | beta,beta Dimethylcysteine | D-3-Mercaptovaline | D 3 Mercaptovaline | Metalcaptase | Cuprimine | Copper Penicillaminate | Penicillaminate, Copper | Cuprenil
Chemical Information
Molecular Formula C5H11NO2S
CAS Registry Number 771431-20-0
SMILES CC(C)(C(C(=O)O)N)S
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal failure20.01.03.005---
Renal vasculitis10.02.02.013; 20.01.07.007; 24.12.04.021---
Sideroblastic anaemia01.03.02.009---
Skin disorder23.03.03.0070.000051%-
Skin hyperpigmentation23.05.01.0030.000113%
Skin wrinkling23.01.03.001---
Stomatitis07.05.06.005--
Synovitis15.04.02.001---
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Thrombocytopenia01.08.01.002---
Thrombocytosis01.08.02.001---
Thrombophlebitis24.01.02.001---
Thrombotic thrombocytopenic purpura01.08.01.005; 23.06.01.011; 24.07.06.014--
Thyroiditis05.02.04.001---
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis10.02.02.006; 24.12.04.027--
Visual impairment06.02.10.013---
Vitamin B6 deficiency14.12.02.005---
Vomiting07.01.07.003--
Yellow nail syndrome22.03.02.001; 23.02.05.009---
Hydrothorax22.05.02.0040.000051%-
Red blood cell sedimentation rate increased13.01.03.001---
Lupus-like syndrome10.04.03.003; 15.06.02.004; 23.03.02.004---
Lymphatic disorder01.09.01.003---
Protein urine present13.13.02.006---
Musculoskeletal discomfort15.03.04.001---
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene